173 related articles for article (PubMed ID: 33369689)
1.
Mittlmeier LM; Unterrainer M; Rodler S; Todica A; Albert NL; Burgard C; Cyran CC; Kunz WG; Ricke J; Bartenstein P; Stief CG; Ilhan H; Staehler M
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2031-2037. PubMed ID: 33369689
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. 18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
Marafi F; Sasikumar A; Aldaas M; Esmail A
Clin Nucl Med; 2021 Jan; 46(1):e65-e67. PubMed ID: 33181733
[TBL] [Abstract][Full Text] [Related]
5. Response assessment using [
Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
[TBL] [Abstract][Full Text] [Related]
6. 18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
Marafi F; Sasikumar A; Al-Terki A; Alfeeli M
Clin Nucl Med; 2020 May; 45(5):377-378. PubMed ID: 32209880
[TBL] [Abstract][Full Text] [Related]
7. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Kelly-Morland C; Rudman S; Nathan P; Mallett S; Montana G; Cook G; Goh V
BMC Cancer; 2017 Jun; 17(1):392. PubMed ID: 28578690
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.
Mytsyk Y; Pasichnyk S; Dutka I; Dats I; Vorobets D; Skrzypczyk M; Uteuliyev Y; Botikova A; Gazdikova K; Kubatka P; Urdzik P; Kruzliak P
Clin Exp Med; 2020 May; 20(2):277-287. PubMed ID: 32026157
[TBL] [Abstract][Full Text] [Related]
10. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
11. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Sadeq A; Usmani S; Esmail AA; Fathallah W; Alfeeli MA; Marafi F
Clin Nucl Med; 2022 Jul; 47(7):627-628. PubMed ID: 35675136
[TBL] [Abstract][Full Text] [Related]
12.
Gao J; Meng L; Xu Q; Zhao X; Deng Y; Fu Y; Guo S; He K; Shi J; Wang F; Zhang S; Guo H
Mol Imaging Biol; 2022 Oct; 24(5):759-768. PubMed ID: 35451707
[TBL] [Abstract][Full Text] [Related]
13.
Mittlmeier LM; Todica A; Gildehaus FJ; Unterrainer M; Beyer L; Brendel M; Albert NL; Ledderose ST; Vettermann FJ; Schott M; Rodler S; Marcon J; Ilhan H; Cyran CC; Stief CG; Staehler M; Bartenstein P
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1711-1720. PubMed ID: 34708249
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT.
Minamimoto R; Nakaigawa N; Tateishi U; Suzuki A; Shizukuishi K; Kishida T; Miura T; Makiyama K; Yao M; Kubota Y; Inoue T
Clin Nucl Med; 2010 Dec; 35(12):918-23. PubMed ID: 21206220
[TBL] [Abstract][Full Text] [Related]
15. Ordered subset expectation maximisation vs Bayesian penalised likelihood reconstruction algorithm in 18F-PSMA-1007 PET/CT.
Witkowska-Patena E; Budzyńska A; Giżewska A; Dziuk M; Walęcka-Mazur A
Ann Nucl Med; 2020 Mar; 34(3):192-199. PubMed ID: 31902120
[TBL] [Abstract][Full Text] [Related]
16. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
[TBL] [Abstract][Full Text] [Related]
17. The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Evangelista L; Basso U; Maruzzo M; Novara G
Eur Urol Focus; 2020 Jan; 6(1):146-150. PubMed ID: 30120074
[TBL] [Abstract][Full Text] [Related]
18. Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy.
Tatar G; Alçin G; Şengül Samanci N; Erol Fenercioglu Ö; Beyhan E; Çermik TF
Nucl Med Commun; 2022 Jun; 43(6):701-709. PubMed ID: 35362692
[TBL] [Abstract][Full Text] [Related]
19. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract][Full Text] [Related]
20. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
